Usted buscó: splenectomy (Inglés - Maltés)

aids-ks patients with splenectomy:
pazjenti aids- ks li tkun tneħħitilhom il- milsa:

aids-related ks patients with splenectomy
pazjenti b’aids-ks minħabba li tkun tneħħitilhom il-milsa

patients who have undergone a splenectomy have an increased risk of pulmonary hypertension.
il- pazjenti li kellhom splenektomija, għandhom żieda fir-riskju għal pressjoni tad-demm pulmonari għolja.

in non-splenectomised patients this should include evaluation relative to splenectomy.
f’pazjenti li ma tneħħitilhomx il- milsa dan għandu jinkludi valutazzjoni rigward it-tneħħija tal-milsa.

as there is no experience with caelyx in patients who have had splenectomy, treatment with caelyx is not recommended.
peress illi mhemmx esperjenza ta 'pazjenti li tkun tneħħitilhom il- milsa t- trattament b’ caelyx mhux rakkomandat.

dose reductions were noted to slow or stop the progression of splenic enlargement and in 3 % of patients a splenectomy was required.
kien hemm bżonn ta’ tnaqqis fid-doża sabiex titnaqqas jew titwaqqaf il-progressjoni taż-żjieda fid-daqs tal-milza u fit-tlieta fil-mija tal-pazjenti kien hemm bżonn li il-milza titneħħa.

dose reductions were noted to slow or stop the progression of splenic enlargement, and in 3% of patients a splenectomy was required.
kien osservat li tnaqqis fid-doża jnaqqas jew iwaqqaf il-progressjoni ta’ tkabbir tal-milsa, u fi 3% tal-pazjenti, splenektomija kienet meħtieġa.

clinical studies comparing eltrombopag to other treatment options (e.g. splenectomy) have not been conducted.
ma saru l-ebda studji kliniċi li jqabblu eltrombopag ma’ għażliet terapewtiċi oħrajn (eż. splenektomija).

in all cases this was mild or moderate on physical examination and the clinical course was benign; no patients had a diagnosis of hypersplenism and no patients underwent splenectomy.
fil-każi kollha, din iż-żjieda nħasset ħafifa jew moderata taħt eżaminazzjoni fiżika u kellha konsegwenza beninni; l-ebda pazjent ġie djanjostikat b’ipersplenismu u fl-ebda pazjent ma tneħħiet il-milza.

in addition to a splenectomy, patients had a median of 6 (range, 3 to 10) treatments for itp prior to study entry.
8 istudju, barra minn tneħħija tal- milsa, l- pazjenti kellhom medjan ta ’ 6 (firxa, 3 sa 10) trattamenti għall - itp.

in all cases of splenic enlargement in hiv patients, this was mild or moderate on physical examination and the clinical course was benign; no patients had a diagnosis of hypersplenism and no patients underwent splenectomy.
fil- każijiet kollha ta’ tkabbir fil-milsa f’pazjenti bl-hiv, dan kien ħafif jew moderat meta sar eżami fiżiku, u l-kors kliniku kien beninn; l-ebda pazjent ma kellu dijanjosi ta’ iperspleniżmu u l-ebda pazjent ma kellu splenektomija.

patients should be clinically evaluated periodically and continuation of treatment should be decided on an individual basis by the treating physician, and in non-splenectomised patients this should include evaluation relative to splenectomy.
il-pazjenti għandhom jiġu evalwati klinikament kull tant żmien u t-tkomplija tal-kura għandha tiġi deċiża mit-tabib li qed jikkura fuq bażi individwali, u f'pazjenti li ma tneħħitilhomx il-milsa dan għandu jinkludi evalwazzjoni relatata mat-tneħħija tal-milsa.

concurrent anaemia and leucocytosis (within a 4-week window) may occur in patients regardless of splenectomy status, but have been seen more often in patients who have had a prior splenectomy.
jista’ jkun hemm anemija u lewkoċitożi fl-istess żmien (f’perjodu ta’ 4 ġimgħat) irrispettivament minn jekk il-pazjenti tneħħitilhomx il-milsa jew le, iżda dawn seħħew aktar frekwentement f’pazjenti li tneħħitilhom il- milsa qabel.

in both raise and tra100773b the response to eltrombopag relative to placebo was similar irrespective of itp medicinal product use, splenectomy status and baseline platelet count (≤ 15,000/µl, > 15,000/µl) at randomisation.
kemm f’raise kif ukoll f’tra100773b ir-rispons għal eltrombopag meta mqabbel mal-plaċebo kien jixxiebah irrispettivament mill-użu ta’ prodott mediċinali għal itp, minn jekk il-milsa tneħħietx jew le, u mill-għadd tal-plejtlits fil-linja bażi (≤ 15,000/µl, > 15,000/µl) meta saret ir-randomisation.